NSIS B — Novozymes A/S Balance Sheet
0.000.00%
- DKK177.14bn
- DKK197.39bn
- €4.16bn
Annual balance sheet for Novozymes A/S, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 140 | 151 | 155 | 284 | 296 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 510 | 581 | 583 | 863 | 915 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,052 | 1,243 | 1,269 | 1,879 | 1,983 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,370 | 1,624 | 1,653 | 2,968 | 2,998 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,331 | 3,764 | 3,809 | 15,196 | 16,349 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 763 | 937 | 974 | 1,088 | 2,741 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,740 | 1,903 | 1,934 | 4,020 | 5,494 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1,591 | 1,861 | 1,875 | 11,176 | 10,855 |
| Total Liabilities & Shareholders' Equity | 3,331 | 3,764 | 3,809 | 15,196 | 16,349 |
| Total Common Shares Outstanding |